Combined Factor Xa and platelet inhibition to prevent recurrent events after ACS: the story so far
Chairperson: P. Gabriel STEG
Objectives:
To understand the dual-pathway strategy for secondary prevention after ACSTo learn about the value of adding rivaroxaban in addition to dual antiplatelet for secondary prevention after ACS
To gain insight into the increasing breadth of oral anticoagulant use in cardiology: the rivaroxaban profile
Lectures
Session objectives
P.G. Steg
The ‘dual antithrombotic pathway’ strategy for ACS secondary prevention: rationale and data
D. Westermann
The added value of Factor Xa inhibition in practice: optimising management of complex ACS cases
A. Kastrati